A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

Brief summary (registry, in English)

To characterize the dose response relationship of FWY003 in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

What you commit to

• Study type: Interventional · Phase 2
• Planned participants: 272
• From 9 Mar 2026 to the primary completion date, 21 Aug 2029
• 68 sites in 19 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 50 or older with geographic atrophy, an eye disease from age-related macular degeneration (AMD), in at least one eye. It compares FWY003 with a placebo.

Age

50 years or older

Sex

Men and women can both join.

Disease stage

Geographic atrophy secondary to AMD in at least one eye (the study eye). Total lesion area must be ≥2.5 and ≤17.5 mm2. A multifocal lesion needs at least one lesion of 1.25 mm2 or more. The whole lesion must be visible on the macula-centered image and not touch peripapillary atrophy.

Earlier treatment

People with previous cell or gene therapy in either eye cannot join. Eye surgery in the study eye within 3 months before baseline is also not allowed.

Biomarker or test result

Vision in the study eye must be ETDRS BCVA ≥ 35 letters (20/200).

Main reasons for not taking part

• Current or past choroidal neovascularization (exudative MNV) in the study eye
• Previous cell or gene therapy in either eye
• Macular atrophy in either eye from a cause other than AMD, such as Stargardt disease or cone rod dystrophy
• Intraocular surgery (including cataract or vitreoretinal) in the study eye within 3 months before baseline
• Significant media opacity, nystagmus, severe ptosis, eye movement restriction or head tremor that would prevent good eye imaging

Read by machine on 10 Nov 2026.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 50 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (68)

Sites in registry order. Save your city in your profile to sort them by distance.

Are you the coordinator? Confirm the details